Search

Additional file 1: Table S1. Information on induced pluripotent stem cell (iPSC) lines used in study. Table S2. Primary antibodies used for immunocytochemistry. Table S3. Secondary antibodies used for immunocytochemistry. Table S4. Primers used for RT-PCR. Figure S1. Polymer characterization data. Figure S2. Representative immunocytochemistry images of iBMEC lines not shown in main manuscript. Figure S3. P-glycoprotein (P-gp) expression and function. Figure S4. TEER measurements for individual cell lines. Figure S5. Additional representative TEM images. Figure S6. Oil-Red-O staining and quantification of WT and ccALD-iPSCs. Figure S7. Timing and dosage effect of polymer treatment.

Additional file 1: Table S1. Information on induced pluripotent stem cell (iPSC) lines used in study. Table S2. Primary antibodies used for immunocytochemistry. Table S3. Secondary antibodies used for immunocytochemistry. Table S4. Primers used for RT-PCR. Figure S1. Polymer characterization data. Figure S2. Representative immunocytochemistry images of iBMEC lines not shown in main manuscript. Figure S3. P-glycoprotein (P-gp) expression and function. Figure S4. TEER measurements for individual cell lines. Figure S5. Additional representative TEM images. Figure S6. Oil-Red-O staining and quantification of WT and ccALD-iPSCs. Figure S7. Timing and dosage effect of polymer treatment.

Dyskeratosis congenita (DC) is a genetic multisystem disorder with frequent involvement of the bone marrow. Haematopoietic stem cell transplantation (HSCT) is the only definitive cure to restore haematopoiesis, even though it cannot correct other organ dysfunctions. We collected data on the outcome of HSCT in the largest cohort of DC (n = 94) patients ever studied. Overall survival (OS) and event-free survival (EFS) at 3 years after HSCT were 66% and 62%, respectively. Multivariate analysis showed better outcomes in patients aged less than 20 years and in patients transplanted from a matched, rather than a mismatched, donor. OS and EFS curves tended to decline over time. Early lethal events were infections, whereas organ damage and secondary malignancies appeared afterwards, even a decade after HSCT. A non-myeloablative conditioning regimen appeared to be most advisable. Organ impairment present before HSCT seemed to favour the development of chronic graft-versus-host disease and T-B immune deficiency appeared to enhance pulmonary fibrosis. According to the present data, HSCT in DC is indicated in cases of progressive marrow failure, whereas in patients with pre-existing organ damage, this should be carefully evaluated. Further efforts to investigate treatment alternatives to HSCT should be encouraged.